No Evidence of Legacy Effect Seen for Intensive Glucose Lowering
WEDNESDAY, June 5, 2019 -- There seems to be no evidence of a legacy effect or mortality benefit for intensive glucose control among military veterans with type 2 diabetes, according to a study published in the June 6 issue of the New England Journal of Medicine.
Peter D. Reaven, M.D., from the Phoenix Veterans Affairs Health Care System, and colleagues report 15-year follow-up for intensive versus standard glucose lowering following a trial involving 1,791 military veterans with type 2 diabetes.
The separation of glycated hemoglobin curves between the intensive- and standard-therapy groups averaged 1.5 points during the trial and declined after the trial ended. The researchers found that the risks for major cardiovascular events or death were not lower in the intensive-therapy group versus the standard-therapy group during a period of 15 years of follow-up (active treatment plus post-trial observation; hazard ratio for primary outcome, 0.91; 95 percent confidence interval, 0.78 to 1.06; P = 0.23; hazard ratio for death, 1.02; 95 percent confidence interval, 0.88 to 1.18). During an extended interval of separation of the glycated hemoglobin curves, the risk for major cardiovascular disease outcomes was reduced (hazard ratio, 0.83; 95 percent confidence interval, 0.70 to 0.99). After equalization of the glycated hemoglobin levels, the benefit did not persist (hazard ratio, 1.26; 95 percent confidence interval, 0.90 to 1.75).
"A major implication of the Veterans Affairs Diabetes Trial follow-up study is that older patients with advanced diabetes should not expect long-term cardiovascular benefits from intensive glycemic control," write the authors of an accompanying editorial.
© 2020 HealthDay. All rights reserved.
Posted: June 2019
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.